CA2557151C - Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite - Google Patents

Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite Download PDF

Info

Publication number
CA2557151C
CA2557151C CA2557151A CA2557151A CA2557151C CA 2557151 C CA2557151 C CA 2557151C CA 2557151 A CA2557151 A CA 2557151A CA 2557151 A CA2557151 A CA 2557151A CA 2557151 C CA2557151 C CA 2557151C
Authority
CA
Canada
Prior art keywords
gip
insulin
glucose
mice
pro3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2557151A
Other languages
English (en)
Other versions
CA2557151A1 (fr
Inventor
Victor A. Gault
Finbarr Paul Mary O'harte
Peter Raymond Flatt
Nigel Irwin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ulster University
Original Assignee
Ulster University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ulster University filed Critical Ulster University
Publication of CA2557151A1 publication Critical patent/CA2557151A1/fr
Application granted granted Critical
Publication of CA2557151C publication Critical patent/CA2557151C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des analogues peptidiques qui sont des antagonistes du peptide inhibiteur gastrique (GIP). Les peptides, sur la base du GIP 1-42, comportent des substitutions et/ou des modifications qui améliorent la résistance à la dégradation par la dipeptidylpeptidase IV (DPP IV). L'invention concerne également un procédé de modification de la terminaison N de GIP ainsi que l'utilisation d'analogues peptidiques destinés au traitement de diabètes.
CA2557151A 2004-02-25 2005-02-25 Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite Active CA2557151C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0404124.0 2004-02-25
GBGB0404124.0A GB0404124D0 (en) 2004-02-25 2004-02-25 Antagonists of GIP
PCT/GB2005/000710 WO2005082928A2 (fr) 2004-02-25 2005-02-25 Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite

Publications (2)

Publication Number Publication Date
CA2557151A1 CA2557151A1 (fr) 2005-09-09
CA2557151C true CA2557151C (fr) 2015-02-17

Family

ID=32050802

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2557151A Active CA2557151C (fr) 2004-02-25 2005-02-25 Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite

Country Status (6)

Country Link
EP (1) EP1730188A2 (fr)
JP (1) JP2008500280A (fr)
AU (1) AU2005217198A1 (fr)
CA (1) CA2557151C (fr)
GB (1) GB0404124D0 (fr)
WO (1) WO2005082928A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI770085B (zh) * 2017-11-21 2022-07-11 日商武田藥品工業股份有限公司 胜肽化合物

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1809335A2 (fr) 2004-10-25 2007-07-25 Cytos Biotechnology AG Systemes d'antigenes de polypeptides inhibiteurs gastriques et utilisations
EP1943274A2 (fr) * 2005-09-08 2008-07-16 Uutech Limited Traitement de l'obesite associee aux diabetes
AU2006289259A1 (en) * 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
WO2007056362A2 (fr) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees
EP2057188B1 (fr) * 2006-08-17 2013-07-31 Amylin Pharmaceuticals, LLC Analogue du gip et polypeptides hybrides possédant des propriétés sélectives
EP2124974B1 (fr) 2007-01-05 2017-03-15 Indiana University Research and Technology Corporation Analogues de glucagon présentant une solubilité améliorée dans des tampons à ph physiologiques
EP2111414B1 (fr) 2007-02-15 2014-07-02 Indiana University Research and Technology Corporation Co-agonistes des récepteurs du glucagon/glp-1
GB0717388D0 (en) * 2007-09-07 2007-10-17 Uutech Ltd Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
WO2009058734A1 (fr) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Composés présentant une activité d'antagoniste de glucagon et d'agoniste du glp-1
ES2509883T3 (es) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Antagonistas de glucagón
WO2009067268A1 (fr) * 2007-11-23 2009-05-28 Michael Rothkopf Procédés d'amplification de la résolution d'un diabète
EA019203B9 (ru) 2008-06-17 2014-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты глюкагонового рецептора/glp-1-рецептора
KR20110039230A (ko) 2008-06-17 2011-04-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체
US9062124B2 (en) 2008-06-17 2015-06-23 Indiana University Research And Technology Corporation GIP-based mixed agonists for treatment of metabolic disorders and obesity
GB0814068D0 (en) * 2008-08-01 2008-09-10 Univ Ulster Active immunisation against GIP
EA020005B1 (ru) * 2008-08-07 2014-07-30 Ипсен Фарма С.А.С. Аналоги глюкозазависимого инсулинотропного полипептида
AU2009280017B2 (en) 2008-08-07 2013-01-10 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
EP2915538A3 (fr) * 2008-08-07 2015-10-14 Ipsen Pharma S.A.S. Analogues tronqués de polypeptide insulinotrope glucose-dépendant
KR101593158B1 (ko) 2008-08-07 2016-02-12 입센 파마 에스.에이.에스. Ｎ-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(ｇｉｐ)의 유사체
TWI489992B (zh) 2008-12-19 2015-07-01 印地安那大學研究及技術公司 醯胺系胰高血糖素超級家族之胜肽前驅藥物
JP5576694B2 (ja) * 2009-04-10 2014-08-20 花王株式会社 Ｇｉｐ上昇抑制剤
MX2011013625A (es) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
EP2512503A4 (fr) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp Co-agonistes du récepteur du glucagon/glp-i
MX2012008603A (es) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
EP2568993A4 (fr) 2010-05-13 2014-02-19 Univ Indiana Res & Tech Corp Peptides de la superfamille du glucagon manifestant une activité de récepteur couplé à une protéine g
ES2661228T3 (es) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
US9023986B2 (en) * 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
PE20140186A1 (es) 2010-12-22 2014-02-13 Univ Indiana Res & Tech Corp Analogos de glucagon que presentan actividad de receptor de gip
JP5914641B2 (ja) * 2011-06-10 2016-05-11 ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． グルコース依存性インスリン分泌刺激ポリペプチドのアナログ、医薬組成物及びその使用
GEP20176629B (en) 2011-06-22 2017-02-27 Indiana Unversity Research And Tech Corporation Glucagon/glp-1 receptor co-agonists
MX2013015168A (es) 2011-06-22 2014-03-31 Univ Indiana Res & Tech Corp Co-agonista del receptor de glucagon/glp-1.
KR20140097151A (ko) 2011-11-17 2014-08-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
JP6311708B2 (ja) 2012-06-21 2018-04-18 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Ｇｉｐ受容体活性を示すグルカゴンアナローグ
EP3985016A1 (fr) 2014-10-29 2022-04-20 Zealand Pharma A/S Composés agonistes de gip et procédés associés
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
ES2972848T3 (es) 2017-05-31 2024-06-17 The Univ Of Copenhagen Análogos de péptido GIP de acción prolongada
EP3788063B1 (fr) * 2018-05-04 2023-08-09 Novo Nordisk A/S Dérivés de gip et leurs utilisations
CN113827706B (zh) * 2021-09-27 2023-12-26 南通大学 Gip及其衍生肽作为制备皮肤创伤治疗药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058360A2 (fr) * 1999-03-29 2000-10-05 Uutech Limited Peptide

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI770085B (zh) * 2017-11-21 2022-07-11 日商武田藥品工業股份有限公司 胜肽化合物

Also Published As

Publication number Publication date
WO2005082928A2 (fr) 2005-09-09
JP2008500280A (ja) 2008-01-10
CA2557151A1 (fr) 2005-09-09
EP1730188A2 (fr) 2006-12-13
WO2005082928A3 (fr) 2005-12-01
GB0404124D0 (en) 2004-03-31
AU2005217198A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
CA2557151C (fr) Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite
US7875587B2 (en) Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
EP1171465B1 (fr) Analogues d'inhibiteur de peptide gastrique et leur utilisation dans le traitement du diabete
JP7211712B2 (ja) グルカゴン受容体アゴニスト
KR102622642B1 (ko) 인크레틴 유사체 및 그의 용도
JP6373270B2 (ja) 二重ｇｌｐ１／グルカゴンアゴニストとしてのエキセンディン−４誘導体
US5604203A (en) Analogs of peptide YY and uses thereof
KR101399178B1 (ko) 선별가능한 특성을 갖는 하이브리드 폴리펩티드
US20090170762A1 (en) Treatment of Diabetes Related Obesity
US20090286722A1 (en) Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function
JP5485876B2 (ja) 代謝疾患の治療における治療剤としての非アシル化グレリン
CZ315594A3 (en) Peptide of glucagon type, insulinotropic derivatives, process of their preparation, pharmaceutical composition containing such compounds and use
KR20210005093A (ko) 아실화된 glp-1 유도체
KR102230368B1 (ko) 아실화 옥신토모듈린 펩타이드 유사체
JP2023544959A (ja) 改善されたアミリン受容体（ｈＡＭＹ３Ｒ）効力を有するｈＡＭ１５－５２類似体
CN115461360A (zh) 持续型glp-1以及胰高血糖素受体双重激动剂
WO2024003359A1 (fr) Agonistes du récepteur de l'amyline (hamy3r) présentant une stabilité chimique améliorée

Legal Events

Date Code Title Description
EEER Examination request